Compare NPKI & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | PHAR |
|---|---|---|
| Founded | 1932 | 1988 |
| Country | United States | Netherlands |
| Employees | 510 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | 2020 |
| Metric | NPKI | PHAR |
|---|---|---|
| Price | $14.38 | $13.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $14.17 | ★ $38.33 |
| AVG Volume (30 Days) | ★ 1.2M | 5.1K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.39 | $10.04 |
| Revenue Next Year | $11.70 | $2.51 |
| P/E Ratio | ★ $38.65 | $3,041.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.63 | $9.54 |
| 52 Week High | $16.50 | $21.34 |
| Indicator | NPKI | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 45.88 | 43.37 |
| Support Level | $14.18 | $12.88 |
| Resistance Level | $15.17 | $13.61 |
| Average True Range (ATR) | 0.56 | 0.47 |
| MACD | -0.02 | -0.08 |
| Stochastic Oscillator | 34.18 | 13.92 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.